
    
      This is a Phase 3 randomized, double-blind, placebo- and active comparator-controlled pivotal
      study. Approximately 500 adult patients with moderate to severe pain due to OA of the knee
      will be enrolled and randomized. All patients will be followed for a total of 52 weeks.
      Efficacy and safety of 2 doses of TLC599 will be evaluated in comparison to Placebo and DSP
      through Week 52.
    
  